Investigating ocrelizumab for relapsing multiple sclerosis patients
The purpose of this study is to find out if an experimental drug could be an alternative therapy for patients who are over 40 years old, have previously been on ocrelizumab (Ocrevus) for at least 18 months, and have relapsing multiple sclerosis (RMS).